Chm-029

Phase 1

CCharm Therapeutics

Chm-029 is one of 7 therapeutic programs targeting AML - Acute Myeloid Leukemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

AML - Acute Myeloid LeukemiaRecruiting

AML - Acute Myeloid LeukemiaPhase 1

Recruiting

Competition

Competitive Landscape

7 competitors in AML - Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Rezlidhia

RRigel Pharmaceuticals

Approved

1 2

Fludara

Sanofi

Phase 2

1 3

Grafapex

MMedexus Pharma, Inc.

Phase 2

1 4

Venclexta

AbbVie

Phase 1

1 5

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 1

1 6

CLN-049

CCullinan Therapeutics Inc.

Phase 1

1 7

Chm-029

CCharm Therapeutics

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1Recruiting

AML - Acute Myeloid Leukemia

NCT07751991

Clinical

Trials by Indication[1]

AML - Acute Myeloid Leukemia1 trial

A Phase 1/2, Multicenter, First-in-Human, Dose Escalation and Expansion Study Evaluating CHM-029 as Monotherapy in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) With NPM1 Mutations, KMT2A or NUP98 Rearrangements

Recruiting·CCharm Therapeutics·Phase 1·NCT07751991·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Chm-029. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Chm-029. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Charm Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: CCharm Therapeutics

Chm-029

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

AML - Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News